BDR Pharma launches patient-friendly prostrate cancer therapy – Times of India

[ad_1] BDR Pharma has introduced BDENZA (Enzalutamide), the world’s first oral solution, designed for the management of prostate cancer. BDENZA will be available at Rs 27,000 for 150mL, in an oral form to reduce the dosing frequency and toxicity associated with the excipients used in marketed formulation, and increase patient compliance, a company statement said….

Read More